

NE/I
7/17/06

Amendments to the Claims

Please amend the claims as shown below.

1.-280. (Canceled)

1 281. (New) Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1), dihydrate.

2 282. (New) A crystalline form of the ^{compound} ~~chemical~~ according to claim 281, characterized by an X-ray powder diffraction pattern having peaks at about 7.1, 9.5, 14.1, 19.6 and 24.5 +/- degrees two-theta.

3 283. (New) The crystalline form of claim 282, further characterized by an X-ray powder diffraction pattern having peaks at about 8.4, 10.2, 12.2, 12.9, 13.2, 15.9, 16.3, 17.7, 18.8, 21.0, 21.7, 23.0, 23.6, 25.9, 26.5, 30.0, and 30.6 ± 0.2 degrees two-theta.

4 284. (New) The crystalline form of claim 282, further characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 5.

5 285. (New) The crystalline form of claim 282, further characterized by a DSC thermal profile showing an endotherm at about 80° C, a melting endotherm at about 188° C and a decomposition endothermic event at about 200° C.

6 286. (New) The crystalline form of claim 282, further characterized by a TGA profile showing a weight loss of about 2.3% to about 2.7% at about 80° C.

7 287. (New) The crystalline form of claim 282, having a stoichiometric value of about 2 to 2.5 moles of water per mole of imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1).

8 288. (New) A solid pharmaceutical composition comprising the crystalline form of claim 282 and at least one pharmaceutically acceptable excipient.

9 289. (New) The solid pharmaceutical composition of claim 288 in a dosage form selected from the group consisting of tablets, pills, capsules, troches, sachets and lozenges.

10 290. (New) The pharmaceutical composition of claim 289 in a dosage form of a tablet.

- 11 291. (New) The pharmaceutical composition of claim 288, wherein the crystalline form is in the form of a powder.
- 12 292. (New) The pharmaceutical composition of claim 291, wherein the powder has a particle size of up to about 200 microns.
- 13 293. (New) The pharmaceutical composition of claim 292, wherein the powder has a particle size of up to about 50 microns.
- 14 294. (New) The pharmaceutical composition of claim 292, wherein the particle size is measured by laser diffraction.
- 15 295. (New) Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, (2R,3R)-2,3-dihydroxybutanedioate, ethanol (2:1:1).
- 16 296. (New) A crystalline form of the ^{compound}~~chemical~~ according to claim 295, characterized by an X-ray powder diffraction pattern having peaks at about 7.1, 9.5, 14.1, 19.6 and 24.5 +/- degrees two-theta.
- 17 297. (New) The crystalline form of claim 296, further characterized by an X-ray powder diffraction pattern having peaks at about 8.4, 10.2, 12.2, 12.9, 13.2, 15.9, 16.3, 17.7, 18.8, 21.0, 21.7, 23.0, 23.6, 25.9, 26.5, 30.0, and 30.6 ± 0.2 degrees two-theta.
- 18 298. (New) The crystalline form of claim 296, further characterized by an X-ray powder diffraction pattern substantially as depicted in Figure 5.
- 19 299. (New) The crystalline form of claim 296, further characterized by a DSC thermal profile showing an endotherm at about 80° C, a melting endotherm at about 188° C and a decomposition endothermic event at about 200° C.
- 20 300. (New) The crystalline form of claim 296, further characterized by a TGA profile showing a weight loss of about 2.3% to about 2.7% at about 80° C.
- 21 301. (New) The crystalline form of claim 296, having a stoichiometric value of about 1 mole of ethanol per mole of imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1).

22 302. (New) A solid pharmaceutical composition comprising the crystalline form of claim 296 and at least one pharmaceutically acceptable excipient.

23 303. (New) The pharmaceutical composition of claim 302 in a dosage form selected from the group consisting of tablets, pills, capsules, troches, sachets and lozenges.

24 304. (New) The pharmaceutical composition of claim 303 in a dosage form of a tablet.

25 305. (New) The pharmaceutical composition of claim 302, wherein the crystalline form is in the form of a powder.

26 306. (New) The pharmaceutical composition of claim 305, wherein the powder has a particle size of up to about 200 microns.

27 307. (New) The pharmaceutical composition of claim 306, wherein the powder has a particle size of up to about 50 microns.

28 308. (New) The pharmaceutical composition of claim 306, wherein the particle size is measured by laser diffraction.